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The production of infectious particles by human immunodeficiency virus type 1 is dependent on the accurate
cleavage of its Gag and Gag/Pol precursors by a virally encoded protease. In the absence of protease activity,
morphologically abnormal particles which are noninfectious are formed. Recently, inhibitors of the protease of
human immunodeficiency virus type 1 have been developed as potential therapeutic agents. We have examined
the basis for the loss of infectivity at the limiting inhibitor concentrations that are likely to be achieved in clinical
settings. We found that subtle defects in processing are correlated with profound deficits in infectivity. Further,
we correlated this partially disrupted processing with an altered virion morphology. These data suggest that
accurate and complete processing is essential to the formation of infectious, morphologically normal virions and
that the pathway by which these precursors are processed and assembled is sensitive to partial inhibition of the
protease by an inhibitor disproportionate to the effect of the inhibitor on the viral protease itself.
The production of infectious retrovirus particles is depen-
dent on the proper assembly of the core particle. The initial
steps in assembly for most retroviruses, including human
immunodeficiency virus type 1 (HIV-1), involve the associ-
ation of the Gag and Gag/Pol precursors with the inner face
of the membrane of the infected cell, followed by interaction
of the precursors with each other (reviewed in reference 6).
The viral protease is part of the larger Gag/Pol precursor and
is only functional as a dimer. This arrangement both allows
the mature proteins which compose the capsid to arrive at
the membrane in a coordinated manner and is largely suc-
cessful in preventing premature activation of the protease.
The membrane-based association of the precursors precedes
cleavage of the precursors by the viral protease and budding
of the mature virus particle which ultimately contains a
collapsed, centrally placed, electron-dense core structure.
Accurate cleavage of the Gag and Gag/Pol precursors by
the viral protease is required for infectivity. In the absence
of protease activity, as in the case of a virus containing a
mutation of the protease active site, morphologically abnor-
mal virus particles which have a distended capsid structure
and are noninfectious are formed (5, 9, 14, 17, 26, 32).
Recently, inhibitors of the protease of HIV-1 have been
developed as potential therapeutic agents. Virus particles
produced by infected cells treated with these inhibitors
contain unprocessed precursors and are noninfectious (1, 7,
12, 15, 16, 21, 22, 29, 30).
Although it has been well established that protease-defi-
cient retroviruses fail to adopt a wild-type morphology and
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are noninfectious, the role played by precursor processing in
virus assembly and the mechanism of the loss of infectivity
remain obscure. We have examined the basis for the loss of
infectivity at the limiting protease inhibitor concentrations
which only partially disrupt processing, a situation that is
likely to be achieved when these inhibitors are used in
clinical settings. We found that subtle defects in processing
are correlated with profound deficits in infectivity. Further,
we correlated this partially disrupted processing with altered
virion morphology and with a reduced capacity to carry out
DNA synthesis. These data suggest that the viral protease
plays an important role in virus assembly and that accurate
and complete processing is essential to the formation of fully
infectious, morphologically normal virions.
MATERIALS AND METHODS
Cells and virus. CEM cells, a human T-cell lymphoma cell
line (a gift of M. Cloyd, University of Texas, Galveston),
were maintained in RPMI 1640 containing 10% (vol/vol) fetal
calf serum. HIV-10 which was isolated from a patient
infected with HIV-1 was the virus isolate used in these
experiments (a gift of M. Cloyd and R. Buckheit). CEM cells
chronically infected with HIV-1 were isolated from acutely
infected cells as described previously (13). Briefly, CEM
cells acutely infected with HIV-10 were pelleted daily by
low-speed centrifugation; the supernatant medium was re-
moved, and the cells were resuspended daily in fresh RPMI
1640 medium with 10% fetal calf serum. A chronically
infected cell line grew out after 2 to 3 weeks. For drug
treatment, cells were placed in a T25 flask at a concentration
of 5 x 104 cells per ml of medium. They were grown for 4
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days in either 0.1% dimethyl sulfoxide (DMSO) or 0.1%
DMSO with various concentrations of the protease inhibitor
A-77003 (12). The cells were then placed in fresh medium
and grown for another 24 h at the same inhibitor concentra-
tion. The supernatant from each culture was used as a source
of virus. Virion proteins were recovered from aliquots of the
supernatant by centrifugation at 100,000 x g for 1.5 h.
Infectivity plaque assay. The focal immunoassay as de-
scribed by Chesebro and Wehrly (4) was used to determine
the titer of virus recovered from chronically infected cells
treated with different concentrations of A-77003. The
amount of pelletable viral protein in each sample was deter-
mined by comparing dilutions of each sample by Western
blot (immunoblot) analysis. An aliquot of 200 ,ul of medium
containing equivalent amounts of viral protein was added to
a well of a 24-well plate containing the CD4+ HeLa cell clone
1022. After 3 days, infected cells were identified by the
presence of syncytia and the coincident immunostaining of
cells with serum from an HIV-infected person and a perox-
idase-conjugated goat anti-human antibody.
Detection of viral DNA. Aliquots of the virus stocks grown
in various concentrations of A-77003 were pelleted by ultra-
centrifugation (100,000 x g for 90 min through a 15% sucrose
cushion). The pellets were resuspended in an amount of
fresh medium such that the concentration of viral protein
was normalized in each specimen, and these were used to
infect cultures ofCEM cells (2 x 106) in duplicate. The cells
and virus were placed at 37°C for either 6 or 10 h, and the
cells were then removed by centrifugation and resuspended
in RIPA buffer (0.15 M NaCl, 20 mM Tris-HCl [pH 7.4], 2
mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 2
,ug of aprotinin per ml, 2 ,ug of leupeptin per ml, 1 ,ug of
pepstatin per ml, 100 ,ug of phenylmethylsulfonyl fluoride
per ml). These samples were subjected to low-speed centrif-
ugation to remove the nuclei. The polymerase chain reaction
was then performed on these supernatants, which represent
combined cytoplasmic and membrane fractions.
To detect viral DNA in infected cells, 25 cycles of poly-
merase chain reaction amplification using a primer pair
specific for the R/U5 region of the viral long terminal repeat
(M667-AA55) was performed as previously described (34,
35). This primer pair can be used to amplify the first 140 bp
of viral DNA that is synthesized following the initiation of
reverse transcription. Briefly, DNA isolated by extraction
with phenol-chloroform was amplified with a single radio-
end-labelled primer (M667) along with the unlabelled an-
tisense primer AA55. Denaturation was accomplished by
heating to 94°C for 1 min; annealing and extension were
accomplished with 65°C for 2 min. Radiolabelled amplified
products were resolved on a 6% polyacrylamide gel, and the
dried gels were subjected to autoradiography. HIV-1 DNA
standards were amplified in parallel to quantitate viral DNA.
The standards consisted of cloned HIV-1 JR-CSF DNA (18)
digested with EcoRI. This DNA was diluted into uninfected
peripheral blood lymphocyte DNA (10 p,g/ml) as a carrier.
RESULTS
Moderate defects in processing result in profound deficits in
infectivity. The Gag precursor of the HIV-1 structural pro-
teins is processed in an ordered manner (10, 13, 23), and
although infectious HIV-1 contains completely processed
precursors, the degree of processing required for infectivity
is unknown. We were interested in characterizing the effects
of low concentrations of a protease inhibitor on processing
and virion assembly. To approach this problem, we treated
CEM cells chronically infected with HIV-1 with several
concentrations of the protease inhibitor A-77003 for 4 days.
At the end of this time, the cells were placed in fresh medium
containing the inhibitor at the same concentration. These
cells were grown for 16 h, at which time they were removed
from the medium by centrifugation and prepared for analysis
by electron microscopy. Aliquots of the supernatant were
assayed for virus titer by the HeLa-CD4 syncytium assay
(4). Virus was recovered from the rest of the supernatant by
centrifugation, and the degree of processing of virion pro-
teins was evaluated by Western analysis.
An examination of the virus titer compared with the extent
of protein processing of the viral proteins at each of the
inhibitor concentrations tested is shown in Fig. 1. Virus
produced from untreated cells had a titer of approximately
7.4 x 103 syncytium-forming units/ml (Fig. 1A), and the viral
proteins recovered from this sample were essentially com-
pletely processed when evaluated with monoclonal antibod-
ies directed against either of the processed Gag products p24
(the viral capsid protein) (Fig. 1B, lane 2) and p17 (the matrix
protein) (Fig. 1B, lane 1). A small amount of the unprocessed
p55 Gag precursor was identified by a monoclonal antibody
to the Gag carboxy-terminal p6 protein (Fig. 1B, lane 3).
When chronically infected cells were grown in the presence
of 0.1 p,M inhibitor, the supernatant virus titer was reduced
by 80%. At this concentration, Western blot analysis re-
vealed that between one-half and two-thirds of the Gag-
derived capsid protein was present as the completely pro-
cessed p24 form (Fig. 1B, lane 5). Most of the remaining
capsid protein was present as part of a processing interme-
diate of approximately 39 kDa. Staining with a monoclonal
antibody directed against p6 (33) demonstrated that, at this
low concentration of inhibitor, there was a small amount of
the p15 processing intermediate composed of the Gag nu-
cleocapsid protein and p6; however, most of the p6 was still
completely processed (Fig. 1B, lane 6). When the cells were
grown in the presence of 0.33 p,M inhibitor, approximately
50% of the virion-associated capsid protein was present as
the 39-kDa species and between 25 and 50% was present as
the completely processed p24 (Fig. 1B, lane 8). In addition,
we estimate that 50% of the matrix protein was present as
completely processed p17 (Fig. 1B, lane 7). At this concen-
tration of inhibitor, however, the virus titer was decreased
between 80- and 100-fold. Finally, at drug concentrations
higher than 0.33 p,M, there were substantial inhibition of
processing and no measurable virus titer. The relative
amounts of the various processing intermediates present in
each sample were evaluated by Western blot analysis of
serial dilutions of each virus-containing supernatant. The
amount of virus used in the infectivity assays was normal-
ized to the amount of viral protein by comparing dilutions of
the different samples by Western blot analysis (data not
shown). In order to assess whether the differences in the
amount of precursor observed could be due to a differential
affinity of the monoclonal antibodies for the precursor, we
repeated the Western analysis with antiserum from an HIV-
1-infected patient and obtained equivalent results (data not
shown). These results demonstrate that under conditions in
which infectivity is reduced nearly 100-fold, there is only
modest inhibition of Gag precursor processing.
A Western blot stained with a monoclonal antibody to the
pol gene product reverse transcriptase (RT) is shown in Fig.
1C. The results are comparable to those seen with the Gag
precursor; at low concentrations of the inhibitor, the pre-
dominant species were the completely processed p66 and
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concentrations of the inhibitor processing intermediates be-
gan to appear. At least 50% of RT was present in its
completely processed forms under conditions in which in-
fectivity was reduced nearly 100-fold. Therefore, the pro-
cessing events required to generate the mature RT do not
appear to be more sensitive to the inhibition than the
processing of Gag, and the modest reduction in processing
seen is inconsistent with the more dramatic drop in infectiv-
ity.
l X 1 0.3 -. 3.0 Partial inhibition of processing results in aberrant virion0.1 3 1 0 morphology. If processing is completely blocked,
Inhibitor Concentration (M) for example, with a high concentration of inhibitor (30) or
with a mutation in the protease domain (9, 17, 26), budded
virions assume a well-described distended or open-circle
shape when thin sections of virus particles are analyzed by
2 3 4 5 6 7 8a 1 0 11 12 13 14 15 electron microscopy. This is in contrast to the electron-
dense, concentrically placed core seen in mature virions. We
were interested in determining the morphology of virions
_ij
_X|withsubtle defects in processing but profound deficits in
infectivity. The infected cells which were used in the exper-
iments described above were fixed and examined by electron
microscopy for the presence of extracellular virus (Fig. 2). A
_ variety of virion morphologies exists in both the treated and
the untreated samples, and different forms predominate at
_ ^ 9 _ different inhibitor concentrations (Fig. 2A to H). The virus
produced from untreated cells contains the characteristic
centrally placed electron-dense core structure (Fig. 2A and
2 3 4 5 E). At an inhibitor concentration of 0.1 ,uM, there is a mix of
normal-appearing virions and virus particles containing ec-
centrically located cores which appear condensed but re-
main attached to the inner face of the viral envelope. At 0.33
,uM, virus particles with these eccentrically placed cores
predominate (Fig. 2B and F), and at the higher concentra-
tions, C shapes and the open forms are most common (Fig.
2C, D, G, and H). In addition to the open forms, there are
also some partially open rings as well as structures that seem
to contain double open rings. These structures have been
erate defects in processing result in profound deficits in observed previously at high concentrations of protease in-
4 cells chronically infected with HIV-1 were isolated hibitors (30). The frequency with which each of these
ected cells as described in Materials and Methods and distinct virion morphologies appears at each inhibitor con-
iese experiments. The chronically infected cells were centration is tabulated in Table 1. In this analysis, we see a
,s in either 0.1% DMSO or 0.1% DMSO with various series of morphologies which correspond to the variable
f the protease inhibitor A-77003. The supernatant from extent of processing. The virtual absence of infectivity in
s harvested and used as a source of virus. Pelletable
as recovered from aliquots of the supematant by those samples in which the aberrant forms predominate
on at 100,000 x g for 1.5 h. (A) Infectivity. The focal suggests that none of the virus particles with altered mor-
i described by Chesebro and Wehrly (4) was used to phology iS infeCtiOUS.
ter of virus recovered from chronically infected cells Aberrantly assembled particles produce reduced amounts of
fferent concentrations of A-77003. The number of viral DNA upon infection of susceptible cells. Although it has
per milliliter was calculated and is shown graphically. long been appreciated that retroviruses which lack function-
umber of infectious units per milliliter is shown in ing proteases are noninfectious, the exact block to infection
Extent of Gag processing. Cell-free supematant was has not been fully characterized. We examined newly in-
infected cells as described above, and equivalent fected cells in order to determine whether reverse transcrip-
ted virion-associated protein were subjected to West- tion of the viral genome occurs. We began by measuring the
e samples were either from untreated cells (lanes 1 to tivtof RT in the occurs. byan exogenous t
treated with different concentrations of A-77003: 0.1 activity of RT in the virus preparations by an exogenous RT
33 (lanes 7 to 9), 1.0 (lanes 10 to 12), or 3 (lanes 13 to assay (Table 2). RT activity was roughly correlated with the
nples were then stained with monoclonal antibodies to degree of processing; however, as in the case with the Gag
ninal p17 matrix protein (lanes 1, 4, 7, 10, and 13), the precursor processing, infectivity decreased out of proportion
in (lanes 2, 5, 8, 11, and 14), or the C-terminal p6 Gag to the modest decline in RT activity.
6, 9, 12, and 15). Monoclonal antibodies to p17 and p24 An analysis of the viral DNA synthesized after infection
Ifrom DuPont (Wilmington, Del.). Monoclonal anti- with virus particles produced at two concentrations of
graciously supplied by F. Veronese (33). (C) Extentof***-aI A-77003 was performed (Fig. 3). Our initial experiments
T. Equivalent amounts of pelleted virion-associated v
p
,,h sample were analyzed by Western blot and stained used polymerase chain primers designed to detect
I antibody directed against the RT of HIV-1 (DuPont). the initial product of reverse transcription. It has been
issociated protein is from untreated cells (lane 1) or suggested that the viral protease acts early in infection, just
0.1 (lane 2), 0.33 (lane 3), 1.0 (lane 4), or 3 (lane 5) ,uM after the virus particle enters the target cell (28). To avoid a
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FIG. 2. Virion morphology is altered by incomplete processing of the Gag precursor. The chronically infected CEM cells used to produce
supernatant for the experiment described in the legend to Fig. 1 were fixed, embedded, and sectioned for electron microscopy. Cells were
grown for 5 days either in 0.1% DMSO (A and E) or in 0.1% DMSO and various concentrations of the inhibitor A-77003: 0.33 (B and F), 1.0
(C and G), and 3.0 (D and H) ,uM.
tants, virus was pelleted from the supernatant and resus-
pended in medium without inhibitor. However, we do not
know whether the inhibitor remained tightly bound to some
fraction of the protease molecules. In the absence of inhib-
itor, there were approximately 1,000 copies of viral DNA
present in the target cells at 6 h after infection (Fig. 3, lane
4). At this same time, there were fewer than 50 copies of
viral DNA in the cells infected with virus grown in the
presence of 0.33 ,uM A-77003 and similar amounts of viral
DNA in the cells grown at 3.0 ,uM (lanes 6 and 8). By 10 h
after infection, the cells infected with the untreated virus
contained approximately 5,000 copies of viral DNA (lane 5),
whereas the cells newly infected with virus produced in the
presence of 0.33 ,uM inhibitor contained 250 copies (lane 7).
Target cells infected for 10 h with virus produced in the
presence of 3.0 pM A-77003 contained only 50 copies of viral
DNA (lane 9). Therefore, little viral DNA was detected
following infection by samples grown in the presence of 3.0
p,M A-77003, and there is an approximately 20-fold reduction
in the initiation of viral DNA synthesis when susceptible
TABLE 1. Virus grown in the presence of different
concentrations of A-77003 exhibits a range of morphologies
Concn Morphologyb,c
6'M)' Wild type Eccentric C-shaped Open
0 123 (86) 14 (10) 4 (3) 2 (1)
0.1 49 (31) 84 (54) 17 (11) 6 (4)
0.33 5 (4) 78 (56) 52 (37) 4 (3)
1.0 0 (0) 9 (5) 56 (32) 110 (63)
3.0 0 (0) 2 (2) 9 (7) 109 (91)
a Cells chronically infected with HIV-1 were grown in the listed concentra-
tions of A-77003 and fixed for electron microscopy.
b Four distinct morphologies were identified (Fig. 2) and quantitated. These
forms are a condensed, centrally placed core (wild type [Fig. 2A]), a
condensed core still associated with the viral membrane (eccentric [Fig. 2B]),
C-shaped electron density associated with the viral membrane (C-shaped [Fig.
2C]), and a mix of open ring structures as well as structures containing double
open rings (open [Fig. 2D]).
c The number of each form of virus seen in thin sections of cells grown in
the indicated concentration of inhibitor is listed, and the percentage of the
total is given in parentheses.
cells are infected with virus grown in the presence of 0.33
,uM inhibitor.
DISCUSSION
Thus far, the only clinically available treatments for HIV
infection are the RT inhibitors 3'-azido-3'-deoxythymidine
and 2',3'-dideoxyinosine. Like RT, the viral protease is an
attractive target for therapeutic intervention. Both are en-
zymes which play critical roles in a complex series of events
in the virus life cycle: RT in the synthesis of double-stranded
DNA from single-stranded RNA and protease in the process-
ing of the Gag and Gag/Pol precursors during virus assem-
bly. The multiple events involved in virus assembly are each
potentially susceptible to inhibition, and to the extent that
the individual events are interdependent, inhibition of one
step may be amplified in its effect by disruption of required
subsequent interactions with other components. Although
the need for accurate processing in the production of prop-
erly assembled (i.e., morphologically normal) and infectious
virus is well established, the impact of subtle defects in the
processing pathway on virus assembly and infectivity has
not been well studied.










a Virus-containing supernatants were obtained from chronically infected
CEM cells treated with the indicated concentrations of inhibitor and assayed
for the presence of RT activity.
b Two representative experiments are shown.
c RT assays were performed as described previously and are reported as
counts per minute of [3HJ1TP incorporated with poly(rA) oligo(dT) as a
template-primer (3).
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FIG. 3. Detection of viral DNA after infection of susceptible
cells. CEM cells were incubated in the presence of virus prepara-
tions produced either in the absence of A-77003 (lanes 4 and 5) or in
the presence of either 0.33 (lanes 6 and 7) or 3.0 (lanes 8 and 9) p.M
inhibitor. The samples were then incubated for either 6 (lanes 4, 6,
and 8) or 10 (lanes 5, 7, and 9) h at 37°C. Negative controls: lane 1,
CEM cells chronically infected with HIV-1; lane 2, HeLa cells
incubated for 10 h with untreated virus; lane 3, CEM cells incubated
in the presence of heat-killed HIV-1.
We have established that a relatively small amount of
protease inhibition resulted in profound declines in virus
infectivity. Krausslich recently noted similar results with
another protease inhibitor (19). Furthermore, we have cor-
related this subtle inhibition of processing with aberrant and
apparently noninfectious virion morphologies. The mecha-
nism by which incomplete protease inhibition results in the
observed morphological change is unclear. The Gag precur-
sor is myristoylated at its amino terminus, and this myris-
toylation has been shown to be important for several differ-
ent retroviruses in directing the precursor to the membrane
(2, 9, 27, 31). The amino-terminal matrix protein remains
associated with the viral membrane after processing (8). It
may be that the eccentrically placed core structures are the
result of incomplete processing at the cleavage site between
the matrix protein and the adjacent capsid protein. This
would be predicted to result in persistent membrane associ-
ation of the otherwise condensed core. These forms predom-
inate at an inhibitor concentration of 0.33 ,uM, and at this
concentration, about 50% of the matrix protein was present
as the mature p17 species with the rest of the matrix protein
remaining linked to the adjacent capsid protein. Support for
this explanation comes from studies in which the matrix-
capsid cleavage site was blocked by mutation, leading to
virus with eccentrically placed cores (9), although our results
would suggest that only a fraction of the matrix protein
needs to remain attached to the collapsed core to produce
this phenotype. The persistent association of the core parti-
cle with the viral membrane is similar to that seen with the B-
and D-type retroviruses. It is possible that incomplete cleav-
age of the C terminus of the matrix protein may also be
responsible for the distinctive morphology of these viruses
(6).
The exact nature of the block to infectivity is also obscure.
The aberrantly assembled particles do not appear to be able
to initiate viral DNA synthesis efficiently upon infection.
Our data indicate that the particles produced from infected
cells grown at a concentration of 0.33 puM A-77003 display an
approximately 20-fold reduction in the initiation of viral
DNA synthesis. This same virus stock has an infectivity
which is decreased 80- to 100-fold compared with that of
virus produced from untreated cells. Since 1 in 20 of the
particles from the cells treated with this concentration is
morphologically normal, it is possible that the viral DNA we
identified is produced by these particles and that improperly
assembled forms are unable to initiate DNA synthesis effi-
ciently.
There are several potential explanations for the failure of
the morphologically abnormal particles to produce viral
DNA. The inability to initiate DNA synthesis may be due to
the inactivity of the unprocessed or partially processed RT.
This seems unlikely since, with an assay based on an
exogenous template, our experiments indicate that total RT
activity is decreased by only approximately one-half at drug
concentrations at which initiation of DNA synthesis is
decreased 20-fold. Other workers have reported differing
amounts of residual RT activity in retroviruses containing
unprocessed Pol precursors whether they were studying
avian leukosis virus (32), murine leukemia virus (5), or
HIV-1 (20, 25). Alternatively, complete proteolytic process-
ing of the Gag precursor may be required for the release of
proteins which are involved in the initiation of reverse
transcription. For example, it has been demonstrated for
Rous sarcoma virus that a fully processed nucleocapsid (NC)
protein is important in maintaining the normal dimeric con-
formation of the viral genome (24, 32). It is unclear whether
monomeric viral genomic RNA can undergo reverse tran-
scription. Another possibility is that residual inhibitor car-
ried in the treated virus stock inhibited the protease, which
caused a failure to cleave the NC protein after infection.
Such a cleavage shortly after infection has been suggested to
enhance infectivity (28), although contradictory results have
been obtained by others (11). Finally, persistent association
of the viral core with the target cell membrane after fusion
may prevent release of the core into the cytoplasm, where
DNA synthesis normally occurs.
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ADDENDUM IN PROOF
Kageyama et al. have reported similar experiments
(Kageyama et al., submitted for publication) and found that
virions made in the presence of A-77003 contain, on average,
less p24 antigen per virion particle when measured by three
different commercially available antigen assay kits.
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